BiotechTube

Lantus® (insulin glargine)

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperglycemia

Conditions

Hyperglycemia, Diabetes Mellitus

Trial Timeline

Feb 1, 2002 → —

NCT ID
NCT00348972

About Lantus® (insulin glargine)

Lantus® (insulin glargine) is a phase 1 stage product being developed by Sanofi for Hyperglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00348972. Target conditions include Hyperglycemia, Diabetes Mellitus.

What happened to similar drugs?

3 of 5 similar drugs in Hyperglycemia were approved

Approved (3) Terminated (2) Active (0)
✅Dapagliflozin + Sliding scale insulinAstraZenecaApproved
✅NPH insulin plus Complete Insulin Orders + Complete Insulin OrdersSanofiApproved
✅insulin glargine + insulin glargine + insulin glargineSanofiApproved
❌Human regular insulin + Insulin lispro + Insulin glargineEli LillyPhase 3
❌insulin glargine recombinant + therapeutic insulinSanofiPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00348972Phase 1Completed

Competing Products

9 competing products in Hyperglycemia

See all competitors
ProductCompanyStageHype Score
Exenatide + InsulinEli LillyPhase 2/3
38
Human regular insulin + Insulin lispro + Insulin glargineEli LillyPhase 3
32
Dapagliflozin + Sliding scale insulinAstraZenecaApproved
43
GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200MerckPhase 1
29
liraglutide + placeboNovo NordiskPre-clinical
26
Olanzapine + ZiprasidonePfizerPre-clinical
26
NPH insulin plus Complete Insulin Orders + Complete Insulin OrdersSanofiApproved
43
insulin glargine + insulin glargine + insulin glargineSanofiApproved
43
insulin glargine recombinant + therapeutic insulinSanofiPhase 3
32